Cargando…

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

AIM: To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying. MATERIALS AND METHODS: This was a randomized, double‐blind, placebo‐controlled, 2‐period, crossover trial. Subjects with obesity (N = 30) received once‐weekly subcutaneous...

Descripción completa

Detalles Bibliográficos
Autores principales: Hjerpsted, Julie B., Flint, Anne, Brooks, Ashley, Axelsen, Mads B., Kvist, Trine, Blundell, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836914/
https://www.ncbi.nlm.nih.gov/pubmed/28941314
http://dx.doi.org/10.1111/dom.13120
_version_ 1783304031575212032
author Hjerpsted, Julie B.
Flint, Anne
Brooks, Ashley
Axelsen, Mads B.
Kvist, Trine
Blundell, John
author_facet Hjerpsted, Julie B.
Flint, Anne
Brooks, Ashley
Axelsen, Mads B.
Kvist, Trine
Blundell, John
author_sort Hjerpsted, Julie B.
collection PubMed
description AIM: To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying. MATERIALS AND METHODS: This was a randomized, double‐blind, placebo‐controlled, 2‐period, crossover trial. Subjects with obesity (N = 30) received once‐weekly subcutaneous semaglutide, dose‐escalated to 1.0 mg, or placebo. After each 12‐week treatment period, glucose and lipid metabolism were assessed before and after standardized meals. Gastric emptying (paracetamol absorption test) and peptide YY (PYY) response were also assessed. RESULTS: Semaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively). Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5 hours [iAUC(0‐5h)]; estimated treatment difference: glucose −1.34 mmol h/L [−2.42, −0.27]; insulin −921 pmol h/L [−1461, −381]; C‐peptide −1.42 nmol h/L [−2.33, −0.51]). Fasting and postprandial lipid metabolism improved with semaglutide vs placebo. First‐hour gastric emptying after the meal was delayed with semaglutide vs placebo (AUC(0‐1h); estimated treatment ratio: 0.73 [0.61, 0.87]); this may have contributed to the lower postprandial glucose increase in semaglutide‐treated subjects. Overall gastric emptying (AUC(0‐5h)) was not statistically different between treatments. Fasting and postprandial PYY responses were significantly lower with semaglutide vs placebo (P = .0397 and P = .0097, respectively). CONCLUSION: Semaglutide improved fasting and postprandial glucose and lipid metabolism. Overall gastric emptying was similar to that with placebo; however, the observed first‐hour delay with semaglutide may contribute to a slower entry of glucose into the circulation.
format Online
Article
Text
id pubmed-5836914
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-58369142018-03-12 Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity Hjerpsted, Julie B. Flint, Anne Brooks, Ashley Axelsen, Mads B. Kvist, Trine Blundell, John Diabetes Obes Metab Original Articles AIM: To investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying. MATERIALS AND METHODS: This was a randomized, double‐blind, placebo‐controlled, 2‐period, crossover trial. Subjects with obesity (N = 30) received once‐weekly subcutaneous semaglutide, dose‐escalated to 1.0 mg, or placebo. After each 12‐week treatment period, glucose and lipid metabolism were assessed before and after standardized meals. Gastric emptying (paracetamol absorption test) and peptide YY (PYY) response were also assessed. RESULTS: Semaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively). Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5 hours [iAUC(0‐5h)]; estimated treatment difference: glucose −1.34 mmol h/L [−2.42, −0.27]; insulin −921 pmol h/L [−1461, −381]; C‐peptide −1.42 nmol h/L [−2.33, −0.51]). Fasting and postprandial lipid metabolism improved with semaglutide vs placebo. First‐hour gastric emptying after the meal was delayed with semaglutide vs placebo (AUC(0‐1h); estimated treatment ratio: 0.73 [0.61, 0.87]); this may have contributed to the lower postprandial glucose increase in semaglutide‐treated subjects. Overall gastric emptying (AUC(0‐5h)) was not statistically different between treatments. Fasting and postprandial PYY responses were significantly lower with semaglutide vs placebo (P = .0397 and P = .0097, respectively). CONCLUSION: Semaglutide improved fasting and postprandial glucose and lipid metabolism. Overall gastric emptying was similar to that with placebo; however, the observed first‐hour delay with semaglutide may contribute to a slower entry of glucose into the circulation. Blackwell Publishing Ltd 2017-10-27 2018-03 /pmc/articles/PMC5836914/ /pubmed/28941314 http://dx.doi.org/10.1111/dom.13120 Text en © 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Hjerpsted, Julie B.
Flint, Anne
Brooks, Ashley
Axelsen, Mads B.
Kvist, Trine
Blundell, John
Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
title Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
title_full Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
title_fullStr Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
title_full_unstemmed Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
title_short Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
title_sort semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836914/
https://www.ncbi.nlm.nih.gov/pubmed/28941314
http://dx.doi.org/10.1111/dom.13120
work_keys_str_mv AT hjerpstedjulieb semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity
AT flintanne semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity
AT brooksashley semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity
AT axelsenmadsb semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity
AT kvisttrine semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity
AT blundelljohn semaglutideimprovespostprandialglucoseandlipidmetabolismanddelaysfirsthourgastricemptyinginsubjectswithobesity